Monty Allen Sells 1,419 Shares of iRadimed (NASDAQ:IRMD) Stock

Key Points

• Director Monty Allen sold 1,419 iRadimed shares for approximately $122,616, reducing his direct stake by 6.76% to 19,581 shares.
• iRadimed reported quarterly EPS of $0.46, beating estimates by $0.02, while revenue of $20.47 million slightly exceeded expectations. The company provided fiscal 2026 EPS guidance of $2.09–$2.24.
• The stock traded near $84.40, with analysts assigning a “Moderate Buy” consensus rating and a $120 average price target; iRadimed also maintains a quarterly dividend of $0.20 per share.

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) Director Monty Allen sold 1,419 shares of the business's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total value of $122,615.79. Following the completion of the sale, the director directly owned 19,581 shares in the company, valued at approximately $1,691,994.21. The trade was a 6.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

iRadimed Stock Performance

Shares of IRMD traded up $0.95 during midday trading on Tuesday, hitting $84.40. 105,400 shares of the stock were exchanged, compared to its average volume of 108,606. iRadimed Corporation has a 52-week low of $67.84 and a 52-week high of $107.90. The stock has a fifty day simple moving average of $91.99 and a 200 day simple moving average of $93.49. The firm has a market cap of $1.08 billion, a P/E ratio of 47.15 and a beta of 0.89.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The firm had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities research analysts forecast that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, August 14th. iRadimed's dividend payout ratio is currently 44.69%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings cut shares of iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, August 3rd. Wall Street Zen cut shares of iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, iRadimed has an average rating of "Moderate Buy" and an average target price of $120.00.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC increased its stake in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider's stock worth $64,000 after buying an additional 107 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after purchasing an additional 234 shares during the last quarter. Quantinno Capital Management LP increased its position in shares of iRadimed by 12.5% in the 1st quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider's stock valued at $335,000 after purchasing an additional 387 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of iRadimed by 10.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,782 shares of the medical equipment provider's stock valued at $466,000 after purchasing an additional 458 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 495 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company's stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.